FDA Staff Raises No Major Safety or Accuracy Concerns With Galleri Multicancer Blood Test

Source Summary

FDA staff members reported no major concerns regarding the safety, accuracy, risks, or benefits of the Galleri multicancer early detection blood test. The assessment comes ahead of an advisory committee meeting scheduled for Wednesday to review the test.

Why it matters

A positive FDA staff assessment strengthens the likelihood of regulatory approval for a blood test that could enable earlier detection of multiple cancer types.

Read the Source

• MedPage Today ↗